NDT Advance Access published online on September 6, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi111
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 INSERM U702, Saint-Antoine University Hospital, University Pierre and Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France
* To whom correspondence should be addressed. Background. Sickle cell disease (SCD) affects the kidney by acute mechanisms as well as by insidious renal medullary/papillary necrosis, resulting in tubular defects, which increase the risk of dehydration and subsequent sickle crisis. Hypoxia has been reported to stimulate endothelin-1 (ET-1) synthesis by endothelial cells and also in the renal tubule. Methods. This case-control study measured ET-1 in urine as a marker of its renal synthesis in asymptomatic SCD patients. Baseline plasma and urinary ET-1 levels were measured and followed during a water deprivation study and a subsequent administration of desmopressin. Results. Urine and plasma levels of ET-1 were elevated in patients with SCD, compared with carefully matched African-French and African controls, and urine ET-1 excretion was associated with a marked urine-concentrating defect. Moreover, urinary ET-1 output was correlated with microalbuminuria in SCD patients. Conclusions. ET-1 is known to antagonize the tubular effects of vasopressin and to promote renal scarring; increased renal production of ET-1 could produce nephrogenic diabetes insipidus and dehydration in SCD patients through a combination of fibrosis and functional resistance to vasopressin. This study provides a rationale for trials with endothelin receptor antagonists in sickle cell disease nephropathy.
Received December 1, 2004
Accepted June 15, 2005
Original Articles
Urinary endothelin-1 as a marker of renal damage in sickle cell disease
2 Department of Day Hospitalization, Saint-Antoine University Hospital, University Pierre and Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France
3 Department of Vascular Medicine, Saint-Antoine University Hospital, University Pierre and Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France
4 Hematology Laboratory; Tenon Hospital, 4 rue de la Chine, 75020, Saint-Antoine University Hospital, University Pierre and Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France
5 INSERM U702, Saint-Antoine University Hospital, University Pierre and Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France; Physiology Laboratory, Saint-Antoine University Hospital, University Pierre and Marie Curie, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France
Pierre-Louis Tharaux, E-mail: pilto{at}bigfoot.com
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. Dhaun, P. Lilitkarntakul, I. M. MacIntyre, E. Muilwijk, N. R. Johnston, D. C. Kluth, D. J. Webb, and J. Goddard Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1477 - F1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF] |
||||

